Several other research firms have also issued reports on AZN. Beaufort Securities reaffirmed a hold rating on shares of Astrazeneca PLC in a research note on Thursday, August 11th. Citigroup Inc. reaffirmed a buy rating on shares of Astrazeneca PLC in a research note on Saturday, June 25th. Jefferies Group raised shares of Astrazeneca PLC from a hold rating to a buy rating in a research report on Monday, September 12th. Shore Capital reissued a hold rating on shares of Astrazeneca PLC in a research report on Wednesday, July 20th. Finally, Argus assumed coverage on shares of Astrazeneca PLC in a research report on Tuesday, July 12th. They set a hold rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $37.49.
Astrazeneca PLC (NYSE:AZN) opened at 32.86 on Wednesday. The company has a 50-day moving average price of $33.37 and a 200-day moving average price of $30.65. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04. The firm has a market capitalization of $83.14 billion, a P/E ratio of 37.55 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. During the same quarter in the previous year, the business earned $1.21 EPS. Astrazeneca PLC’s quarterly revenue was down 4.0% compared to the same quarter last year. On average, equities research analysts predict that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.
The business also recently announced a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
Several institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. raised its position in shares of Astrazeneca PLC by 308.7% in the second quarter. Macquarie Group Ltd. now owns 138,966 shares of the company’s stock worth $4,195,000 after buying an additional 104,967 shares during the last quarter. Beacon Trust Co. bought a new position in shares of Astrazeneca PLC during the second quarter worth about $211,000. IFP Advisors Inc raised its position in shares of Astrazeneca PLC by 18.9% in the second quarter. IFP Advisors Inc now owns 18,652 shares of the company’s stock worth $563,000 after buying an additional 2,966 shares during the last quarter. Stifel Financial Corp raised its position in shares of Astrazeneca PLC by 7.6% in the second quarter. Stifel Financial Corp now owns 179,384 shares of the company’s stock worth $5,416,000 after buying an additional 12,602 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Astrazeneca PLC by 939.7% in the second quarter. Legal & General Group Plc now owns 22,239 shares of the company’s stock worth $672,000 after buying an additional 20,100 shares during the last quarter. Institutional investors own 11.39% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.